Tick-Borne Diseases in Dogs: Comprehensive Pathogen List, Curability, and Clinical Management

Introduction

Tick-borne diseases represent a significant and growing category of infectious diseases in canine medicine. The geographic expansion of tick vectors, driven by climate change and habitat alteration, has increased the exposure of domestic dogs to a diverse array of bacterial, protozoal, and viral pathogens transmitted during tick feeding. This article provides a comprehensive reference for veterinary professionals on the complete list of tick-borne pathogens affecting dogs, the curability of each infection, and evidence-based clinical management strategies. The focus is exclusively on canine disease, with no discussion of human clinical trials or human medicine.

Comprehensive Pathogen List

Tick-borne pathogens in dogs can be classified into three major groups: bacteria (including rickettsial organisms), protozoa, and viruses. The following table provides a complete list of confirmed tick-borne pathogens in dogs, their primary tick vectors, and the disease syndromes they cause.

Curability of Tick-Borne Diseases in Dogs

The question "are tick borne diseases in dogs curable" requires a pathogen-specific answer. Curability depends on the biology of the organism, its intracellular niche, and the availability of antimicrobial agents that achieve sterilizing clearance.

Bacterial Infections (Curable with Appropriate Therapy)

Lyme disease (Borrelia burgdorferi). Doxycycline administered at 10 mg/kg orally every 24 hours for 30 days is the standard of care. This regimen achieves clinical resolution in the majority of cases. However, seroreversion (negative antibody test after treatment) is uncommon, and dogs may remain seropositive for months to years despite apparent clearance of the spirochete. True microbiologic cure is achievable, but persistent infection in sequestered sites (e.g., joints, connective tissue) has been documented in experimental models.

Anaplasma phagocytophilum and Anaplasma platys. Doxycycline at 10 mg/kg orally every 24 hours for 14 to 21 days is highly effective. Clinical signs typically resolve within 24 to 48 hours of therapy initiation. Microbiologic cure is achievable, and seroreversion can occur over several months.

Ehrlichia canis and Ehrlichia ewingii. Doxycycline at 10 mg/kg orally every 24 hours for 28 days is the recommended protocol. For E. canis, the acute phase is highly responsive, but the chronic phase may be more refractory. Persistent infection despite treatment has been documented, particularly in dogs with chronic monocytic ehrlichiosis. In such cases, combination therapy with doxycycline and a fluoroquinolone (e.g., enrofloxacin) may be considered, though evidence for superior efficacy is limited.

Rickettsia rickettsii. Doxycycline at 5 mg/kg orally every 12 hours or 10 mg/kg every 24 hours for 7 to 14 days is curative. Clinical improvement is rapid, often within 24 to 48 hours.

Francisella tularensis. Streptomycin (10 to 15 mg/kg intramuscularly every 12 hours) or gentamicin (6 to 10 mg/kg subcutaneously every 24 hours) for 7 to 14 days is recommended. Doxycycline is a second-line agent. Cure is achievable with appropriate therapy.

Bartonella vinsonii subsp. berkhoffii. Treatment is challenging and often requires prolonged therapy with azithromycin (5 to 10 mg/kg orally every 24 hours) or doxycycline combined with rifampin. Complete microbiologic cure is difficult to confirm, and relapses are documented.

Mycoplasma haemocanis and Candidatus Mycoplasma haematoparvum. Doxycycline at 10 mg/kg orally every 24 hours for 14 to 21 days is effective. In severe anemia, a single dose of imidocarb dipropionate (5 to 6.6 mg/kg intramuscularly) may be used. Cure is achievable.

Protozoal Infections (Suppression Rather Than Sterilizing Cure)

Babesia canis, Babesia vogeli, Babesia gibsoni, and Babesia conradae. No treatment achieves consistent sterilizing cure. Imidocarb dipropionate (5 to 6.6 mg/kg intramuscularly, repeated once after 14 days) is the standard therapy for B. canis and B. vogeli. For B. gibsoni, a combination of atovaquone (13.5 mg/kg orally every 8 hours) and azithromycin (10 mg/kg orally every 24 hours) for 10 days is recommended. Clinical resolution is common, but polymerase chain reaction (PCR) negativity is not always achieved, and dogs may remain subclinically infected carriers.

Hepatozoon canis and Hepatozoon americanum. Treatment is suppressive rather than curative. For H. canis, imidocarb dipropionate (5 to 6.6 mg/kg intramuscularly every 14 days for 2 to 3 treatments) is used. For H. americanum, a combination of trimethoprim-sulfadiazine (15 mg/kg orally every 12 hours), pyrimethamine (0.25 mg/kg orally every 24 hours), and clindamycin (10 mg/kg orally every 12 hours) for 14 days, followed by long-term decoquinate (20 mg/kg orally every 12 hours with food) for suppression, is the standard protocol. Relapse is common after discontinuation of therapy.

Summary of Curability

Clinical Management Protocols

Diagnostic Approach

The diagnostic workup for suspected tick-borne disease in dogs should integrate hematologic, serologic, and molecular methods. Complete blood count (CBC) using automated impedance analyzers may reveal thrombocytopenia (common in ehrlichiosis, anaplasmosis, and babesiosis), anemia (babesiosis, hemoplasmosis), or leukopenia (ehrlichiosis). Serum biochemistry may show hyperglobulinemia (chronic ehrlichiosis) or azotemia (Lyme nephropathy).

Serologic testing using commercial enzyme-linked immunosorbent assay (ELISA) kits for in-clinic use detects antibodies against B. burgdorferi, A. phagocytophilum, A. platys, and E. canis. The ELISA for Feline Leukemia Virus p27 antigen detection provides a useful parallel for understanding antigen versus antibody detection principles, though the target pathogen is different. For tick-borne diseases, serology indicates exposure but cannot distinguish active infection from past exposure.

Molecular diagnostics using real-time PCR assays on whole blood or buffy coat provide definitive evidence of active infection. PCR is particularly valuable for Babesia spp., where serology may be unreliable due to low antibody titers in acute infection. For Hepatozoon spp., PCR on blood or muscle biopsy is the diagnostic method of choice.

Treatment Algorithms

The following Mermaid diagram illustrates a clinical decision tree for managing a dog with suspected tick-borne disease.

flowchart TD
    A[Dog with suspected tick-borne disease], > B{Clinical signs present?}
    B, >|Yes| C[Perform CBC, serum chemistry, serology, PCR]
    B, >|No| D[Annual screening serology in endemic areas]
    C, > E{Thrombocytopenia or anemia?}
    E, >|Yes| F[High suspicion for Ehrlichia, Anaplasma, or Babesia]
    E, >|No| G[Consider Lyme disease, Bartonella, or other pathogens]
    F, > H[Start doxycycline 10 mg/kg q24h empirically]
    H, > I{PCR results available?}
    I, >|Ehrlichia or Anaplasma positive| J[Continue doxycycline for 28 days]
    I, >|Babesia positive| K[Switch to imidocarb or atovaquone/azithromycin]
    I, >|Negative| L[Re-evaluate for other causes]
    G, > M[Lyme C6 antibody test and urine protein:creatinine ratio]
    M, > N{Proteinuria present?}
    N, >|Yes| O[Treat with doxycycline 30 days + monitor renal function]
    N, >|No| P[Doxycycline 30 days, monitor clinical response]
    J, > Q[Recheck CBC at 14 days]
    Q, > R{Platelet count normalized?}
    R, >|Yes| S[Complete 28-day course]
    R, >|No| T[Consider chronic ehrlichiosis, extend therapy]
    K, > U[Recheck PCR at 30 days]
    U, > V{PCR negative?}
    V, >|Yes| W[Clinical cure achieved, monitor for relapse]
    V, >|No| X[Consider second treatment course or alternative protocol]

Specific Pathogen Management

Lyme disease (Borrelia burgdorferi). Doxycycline for 30 days is the cornerstone. Dogs with Lyme nephropathy (proteinuric kidney disease) require aggressive management including angiotensin-converting enzyme inhibitors, omega-3 fatty acids, and dietary protein restriction. The prognosis for Lyme nephropathy is guarded to poor.

Ehrlichiosis (Ehrlichia canis). Acute cases respond well to doxycycline. Chronic cases may require extended therapy (6 to 8 weeks) and supportive care including fluid therapy and blood transfusion for severe thrombocytopenia. Glucocorticoids are contraindicated in the acute phase but may be considered in immune-mediated thrombocytopenia secondary to chronic ehrlichiosis.

Anaplasmosis (Anaplasma phagocytophilum and Anaplasma platys). Doxycycline for 14 to 21 days is sufficient. Clinical improvement is rapid. For A. platys, the cyclic thrombocytopenia resolves within days of therapy.

Babesiosis (Babesia spp.). Imidocarb dipropionate is effective for B. canis and B. vogeli. For B. gibsoni, atovaquone and azithromycin combination therapy is preferred. Supportive care includes intravenous fluids, blood transfusion for severe anemia, and monitoring for hemolytic crisis. Dogs that remain PCR positive after treatment may require a second course or alternative therapy such as clindamycin.

Hepatozoonosis (Hepatozoon americanum). This is the most challenging tick-borne disease to manage. Acute therapy with trimethoprim-sulfadiazine, pyrimethamine, and clindamycin for 14 days is followed by long-term decoquinate administration. Nonsteroidal anti-inflammatory drugs are used to manage the severe myositis and periosteal bone proliferation. Relapse is expected, and lifelong therapy may be necessary.

Prevention

Tick control is the primary prevention strategy. Isoxazoline class ectoparasiticides (e.g., afoxolaner, fluralaner, sarolaner, lotilaner) provide rapid tick kill and are highly effective. Monthly administration of these agents reduces the risk of pathogen transmission. For Lyme disease, vaccination with recombinant OspA vaccines is available and provides additional protection in endemic areas. No vaccines are commercially available for other tick-borne pathogens in dogs.

Conclusion

Tick-borne diseases in dogs encompass a diverse group of bacterial and protozoal pathogens with varying curability. Bacterial infections including Lyme disease, anaplasmosis, and ehrlichiosis are curable with appropriate doxycycline therapy. Protozoal infections such as babesiosis and hepatozoonosis are suppressible but not reliably cured, and dogs may remain subclinical carriers. Accurate diagnosis using integrated serologic and molecular methods, combined with pathogen-specific treatment protocols, is essential for optimal clinical outcomes. Tick prevention remains the cornerstone of disease management.

References

1. Little SE. Ehrlichiosis and anaplasmosis in dogs and cats. Veterinary Clinics of North America: Small Animal Practice. 2010;40(6):1121-1140.
2. Kidd L, Breitschwerdt EB. Transmission times and prevention of tick-borne diseases in dogs. Compendium on Continuing Education for the Practicing Veterinarian. 2003;25(10):742-751.
3. Birkenheuer AJ, Levy MG, Breitschwerdt EB. Development and evaluation of a seminested PCR for detection and differentiation of Babesia gibsoni (Asian genotype) and B. canis DNA in canine blood samples. Journal of Clinical Microbiology. 2003;41(9):4172-4177.
4. Neer TM, Breitschwerdt EB, Greene RT, et al. Consensus statement on ehrlichial disease of small animals from the infectious disease study group of the ACVIM. Journal of Veterinary Internal Medicine. 2002;16(3):309-315.
5. Littman MP, Goldstein RE, Labato MA, et al. ACVIM small animal consensus statement on Lyme disease in dogs: diagnosis, treatment, and prevention. Journal of Veterinary Internal Medicine. 2006;20(2):422-434.
6. Macintire DK, Vincent-Johnson N, Dillon AR, et al. Hepatozoonosis in dogs: 22 cases (1989-1994). Journal of the American Veterinary Medical Association. 1997;210(7):916-922.
7. Greene CE. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier Saunders; 2012.
8. Shaw SE, Day MJ, Birtles RJ, et al. Tick-borne infectious diseases of dogs. Trends in Parasitology. 2001;17(2):74-80.